Two-Step Targeted Hybrid Nanoconstructs Increase Brain Penetration and Efficacy of the Therapeutic Antibody Trastuzumab against Brain Metastasis of HER2-Positive Breast Cancer

He, C., Li, J., Cai, P., Ahmed, T., Henderson, J. T., Foltz, W. D., & Wu, X. Y.

Advanced Functional Materials 28.9 (2018): 1705668.

Therapeutic antibodies (e.g., trastuzumab, TRA) against human epidermal growth factor receptor 2 (HER2)-positive breast cancers have shown benefits in controlling primary tumors, yet are ineffective against brain metastases due to their inability to cross the blood-brain barrier (BBB). A novel hybrid nanoconstruct system is designed to deliver trastuzumab to brain metastasis of HER2-positive breast cancer via a two-step sequential targeting approach. Self-assembly of a polysorbate 80 (PS 80)-containing polymer, lipid, and polymer-conjugated TRA forms hybrid nanoconstructs (TRA-terpolymer nanoparticles (TPN)) with high encapsulation efficiency and bioactivity. The PS 80 moiety enables the first-step targeting and receptor-mediated trancytosis across BBB is demonstrated in vitro with a 3D human BBB model in healthy and brain tumor-bearing mice. The subsequent partial dissociation of the nanoconstructs exposes the encapsulated TRA for the second-step targeting to HER2-positive cancer cells in the brain. Intravenously injected TRA-TPN delivers 50-fold TRA compared to free TRA to the brain metastasis of HER2-positive breast cancer. Treatment with TRA-TPN increases tumor cell apoptosis by 4-fold, inhibits tumor growth by 43-fold, and prolongs median survival by >1.3-fold compared to free TRA, without causing noticeable organ toxicity. These findings suggest the two-step targeted nanoconstruct system is promising for shuttling therapeutic antibodies to treat central nervous system diseases.

Two-Step-Targeted-Hybrid-Nanoconstructs-Increase-Brain-Penetration-and-Efficacy-of-the-Therapeutic-Antibody-Trastuzumab-against-Brain-Metastasis-of-HER2-Positive-Breast-Cancer

Products Used in this Publication

Catalog NumberCASProduct NamePrice
B0084-061382180288-69-1TrastuzumabInquiry

Related Products

Catalog NumberCASProduct NamePrice
B0084-086248183321-74-6ErlotinibInquiry
B0084-2867771213269-23-8WZ-4002Inquiry
B0084-4575421204313-51-8Icotinib HydrochlorideInquiry
B0084-4708421353550-13-6OlmutinibInquiry
B0084-4745991508250-71-2EGF816Inquiry